Skip to main content

Erleada FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 19, 2019.

FDA Approved: Yes (First approved February 14, 2018)
Brand name: Erleada
Generic name: apalutamide
Dosage form: Tablets
Company: Johnson & Johnson Innovative Medicine
Treatment for: Prostate Cancer

Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of metastatic castration-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer.

Development timeline for Erleada

DateArticle
May  3, 2024Phase 2 data for Erleada plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer results published
Jan 31, 2024First Patient Dosed in Phase 2 Trial of ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer
Apr 12, 2023ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
Sep 17, 2019Approval FDA Approves Erleada (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Feb 14, 2018Approval FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer
Oct 11, 2017Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer

See also

Erleada (apalutamide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer